The global female sexual dysfunction treatment market is expected to grow at a significant CAGR during the forecast period (2021-2027). Sexual dysfunction is a medical disorder characterized by an inability to achieve sexual arousal on a consistent or recurring basis. Primary care physicians are commonly sought for treatment of this dysfunction; however, erectile dysfunction (ED) doctors can also be consulted. Women have been found to be more susceptible to sexual dysfunction than men. Female sexual dysfunction can develop at any age and can be persistent or sporadic. Physical or psychological issues can cause sexual dysfunction. Heart and neurological problems, hormone imbalances, diabetes, and menopause are all instances of physical disorders.
A full report of Female Sexual Dysfunction Treatment Market is available at: https://www.omrglobal.com/industry-reports/female-sexual-dyfunction-treatment-market
Overweight, hypertension, metabolic disease, and atherogenic dyslipidemia are all risk factors for female sexual dysfunction in diabetic patients. As a result, the increasing prevalence of these illnesses around the world is expected to expand the patient pool, resulting in a large number of women with sexual dysfunctions, driving the demand for female sexual dysfunction treatment. The dopamine receptor bar is responsible for the majority of sexual dysfunction. As a result, the use of such pharmaceuticals will increase the incidences of sexual dysfunctions in women. Therefore, there is an increasing demand for medications to treat sexual dysfunctions in women.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/female-sexual-dyfunction-treatment-market
Sexual dysfunction is also caused by chronic disorders such as alcoholism, kidney disease, liver disease, and drug misuse. Anxiety, work-related stress, marital issues, and past trauma are instances of psychological disorders that cause sexual dysfunction. Due to an increase in the rates of female sexual dysfunction and increased awareness about it, the global market for female sexual dysfunction is rising at a significant rate. The global female sexual dysfunction treatment market has been driven by increased awareness, technological advancements, and a high acceptance rate of sexual dysfunction treatment. However, lack of awareness about the treatment in some countries, as well as social hurdles, are limiting the global female sexual dysfunction treatment market. Furthermore, the market is hampered by the social, and reimbursement difficulties. The female sexual dysfunction treatment market is predicted to grow in developing countries like India and China owing to the rising awareness regarding sexual condition in these countries.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Apricus Biosciences, Inc., GlaxoSmithKline, plc., and Pfizer, Inc. among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Female Sexual Dysfunction Treatment Market Report Segmentation
By Type
• Hormonal Therapy
• Non-Hormonal therapy
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
